RU2711629C1 - Method for treating influenza and quinsy strains and composition for its implementation - Google Patents

Method for treating influenza and quinsy strains and composition for its implementation Download PDF

Info

Publication number
RU2711629C1
RU2711629C1 RU2018139177A RU2018139177A RU2711629C1 RU 2711629 C1 RU2711629 C1 RU 2711629C1 RU 2018139177 A RU2018139177 A RU 2018139177A RU 2018139177 A RU2018139177 A RU 2018139177A RU 2711629 C1 RU2711629 C1 RU 2711629C1
Authority
RU
Russia
Prior art keywords
iridium
immune system
influenza
metabolic processes
angina
Prior art date
Application number
RU2018139177A
Other languages
Russian (ru)
Inventor
Артур Витович Жиурис
Original Assignee
Артур Витович Жиурис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Артур Витович Жиурис filed Critical Артур Витович Жиурис
Priority to RU2018139177A priority Critical patent/RU2711629C1/en
Application granted granted Critical
Publication of RU2711629C1 publication Critical patent/RU2711629C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: medicine.SUBSTANCE: invention refers to medicine and represents a method for stimulating the immune system and activating metabolic processes in influenza or angina, involving administering a composition containing powdered following components, wt%: osmous iridium with aconite 1: 10,000 1–3; osmosis iridium with toxic agent 1:10,000 1–3; potassium phosphated monosubstituted with celandine 1:1 20–30; sodium carbonate with pomegranate grains 1:1 20–30; ethylenediamine with St. John's wort 1:5 20–30; ascorbic acid with carrot tops 1:10 rest, course of 30 days with daily 4-time intake through gastrointestinal tract 0.1 g 30 minutes before meals.EFFECT: use of the declared invention enables effective stimulation of the immune system and activation of metabolic processes in influenza and angina.1 cl, 3 tbl, 1 ex

Description

Изобретение относится к здравоохранению и может быть использовано при лечении штаммов гриппа и ангины.The invention relates to healthcare and can be used in the treatment of strains of influenza and tonsillitis.

Известен способ стимуляции иммунной системы человека, включающий введение терапевтических доз соединений минерала осмистый иридий раздельно с мумие и прополисом в соотношениях 1:1000, изготавливаемых при воздействии температуры и давления [RU Пат. 2346696 А61К 33/00].A known method of stimulating the human immune system, including the introduction of therapeutic doses of mineral compounds osmoid iridium separately with mummy and propolis in ratios of 1: 1000, made under the influence of temperature and pressure [RU Pat. 2346696 A61K 33/00].

Недостатком данного способа является необоснованно высокая стоимость лечения и некоторый дискомфорт.The disadvantage of this method is the unreasonably high cost of treatment and some discomfort.

Цель изобретения - снижение стоимости лечения при улучшении комфорта.The purpose of the invention is to reduce the cost of treatment while improving comfort.

Поставленная задача достигается тем, что состав содержит порошкообразные следующие компоненты в массе %:The problem is achieved in that the composition contains the following powdered components in mass%:

Осмистый иридий с аконитом (1:10000)Osmisty iridium with aconite (1: 10000) - 1-3;- 1-3; Осмистый иридий с вех ядовитый (1:10000)Osmisty iridium with poisonous milestones (1: 10000) - 1-3;- 1-3; Калий фосфорнокислотный однозамещенный с чистотелом (1:1)Potassium phosphate monosubstituted with celandine (1: 1) - 20-30;- 20-30; Натрий углекислый с зернами граната (1:1)Sodium carbonate with pomegranate seeds (1: 1) - 20-30;- 20-30; Этилендиамин со зверобоем (1:5)Ethylene diamine with Hypericum (1: 5) - 20-30;- 20-30; Аскорбиновая кислота с морковной ботвой (1:10)Ascorbic acid with carrot tops (1:10) - остальное.- the rest.

При снижении уровня осмистого иридия с аконитом и вехом ядовитым менее 1% лечение затягивается на неопределенное время, а более 3% необоснованно повышается стоимость.With a decrease in the level of osmoid iridium with aconite and poisonous milestone less than 1%, the treatment is delayed indefinitely, and more than 3% the cost unreasonably increases.

При снижении уровня калия фосфорнокислого однозамещенного с чистотелом, натрия углекислого с зернами граната, этилендиамина со зверобоем каждого менее 20% - снижается метаболизм, а более 30% каждого необоснованно повышается стоимость.With a decrease in the level of potassium phosphate monosubstituted with celandine, sodium carbonate with pomegranate seeds, ethylenediamine with St. John's wort each less than 20%, the metabolism decreases, and more than 30% of each unreasonably increases the cost.

Пример конкретного применения см. табл. №1, 2, 3 изготовили состав, содержащий следующие компоненты в массе %:An example of a specific application, see table. No. 1, 2, 3 made a composition containing the following components in mass%:

Осмистый иридий с аконитом (1:10000)Osmisty iridium with aconite (1: 10000) - 2,- 2, Осмистый иридий с вех ядовитый (1:10000)Osmisty iridium with poisonous milestones (1: 10000) - 2,- 2, Калий фосфорнокислый однозамещенный с чистотелом (1:1)Potassium phosphate monosubstituted with celandine (1: 1) - 25,- 25, Натрий углекислый с зернами граната (1:1)Sodium carbonate with pomegranate seeds (1: 1) - 25,- 25, Этилендиамин со зверобоем (1:5)Ethylene diamine with Hypericum (1: 5) - 25,- 25, Аскорбиновая кислота с морковной ботвой (1:10)Ascorbic acid with carrot tops (1:10) - остальное.- the rest.

Проведенный курс лечения 30 дней, при ежедневном 4-х разовом приеме через желудочно-кишечный тракт состава разовым приемом по 0,1 гр. за 30 минут до приема пищи показал следующие результаты (см. табл. №1, 2, 3).The course of treatment was 30 days, with a daily 4 single dose through the gastrointestinal tract of a single dose of 0.1 g. 30 minutes before a meal showed the following results (see table. No. 1, 2, 3).

Результаты проведенных исследований подтвердили стимулирование иммунной системы (см. табл. №3) и активации обменных процессов (см. табл. №1, 2).The results of the studies confirmed the stimulation of the immune system (see table. No. 3) and the activation of metabolic processes (see table. No. 1, 2).

Figure 00000001
Figure 00000001

Figure 00000002
Figure 00000002

Figure 00000003
Figure 00000003

Claims (3)

Способ стимулирования иммунной системы и активации обменных процессов при гриппе или ангине, включающий введение состава, содержащего порошкообразные следующие компоненты, мас. %:A method of stimulating the immune system and activating metabolic processes in case of flu or sore throat, comprising administering a composition containing the following powdered components, wt. %: Осмистый иридий с аконитом 1:10000Osmisty iridium with aconite 1: 10000 1 - 3 thirteen Осмистый иридий с вехом ядовитым 1:10000Osmisty iridium with a milestone poisonous 1: 10000 1 - 3  thirteen Калий фосфорнокислый однозамещенный с чистотелом 1:1Potassium phosphate monosubstituted with celandine 1: 1 20 - 30 20 - 30 Натрий углекислый с зернами граната 1:1Sodium carbonate with pomegranate seeds 1: 1 20 - 30  20 - 30 Этилендиамин со зверобоем 1:5Ethylene diamine with Hypericum 1: 5 20 - 30  20 - 30 Аскорбиновая кислота с морковной ботвой 1:10Ascorbic acid with carrot tops 1:10 остальное   rest
курсом 30 дней при ежедневном 4-разовом приеме через желудочно-кишечный тракт по 0,1 г за 30 минут до приема пищи.a course of 30 days with a daily 4-time intake through the gastrointestinal tract of 0.1 g 30 minutes before a meal.
RU2018139177A 2018-11-06 2018-11-06 Method for treating influenza and quinsy strains and composition for its implementation RU2711629C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2018139177A RU2711629C1 (en) 2018-11-06 2018-11-06 Method for treating influenza and quinsy strains and composition for its implementation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018139177A RU2711629C1 (en) 2018-11-06 2018-11-06 Method for treating influenza and quinsy strains and composition for its implementation

Publications (1)

Publication Number Publication Date
RU2711629C1 true RU2711629C1 (en) 2020-01-17

Family

ID=69171392

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018139177A RU2711629C1 (en) 2018-11-06 2018-11-06 Method for treating influenza and quinsy strains and composition for its implementation

Country Status (1)

Country Link
RU (1) RU2711629C1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006228C1 (en) * 1992-03-26 1994-01-30 Александр Михайлович Шепеленко Compound for treating influenza
RU2245157C2 (en) * 2001-08-09 2005-01-27 Общество с ограниченной ответственностью "ЛЕОВИТ нутрио" (ООО "ЛЕОВИТ нутрио") Biologically active additive for preventing and treating flu cases
RU2346696C2 (en) * 2006-06-29 2009-02-20 Геннадий Михайлович Яковлев Method of human immune system stimulation using activated platinoids-containing mineral, method of mineral activation and composition with immune system stimulation properties
RU2396734C1 (en) * 2009-04-30 2010-08-10 Наталья Геннадьевна Яковлева Resistance thin-film heater composition to use electromagnetic radiation for activating metabolism and stimulating human immune system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006228C1 (en) * 1992-03-26 1994-01-30 Александр Михайлович Шепеленко Compound for treating influenza
RU2245157C2 (en) * 2001-08-09 2005-01-27 Общество с ограниченной ответственностью "ЛЕОВИТ нутрио" (ООО "ЛЕОВИТ нутрио") Biologically active additive for preventing and treating flu cases
RU2346696C2 (en) * 2006-06-29 2009-02-20 Геннадий Михайлович Яковлев Method of human immune system stimulation using activated platinoids-containing mineral, method of mineral activation and composition with immune system stimulation properties
RU2396734C1 (en) * 2009-04-30 2010-08-10 Наталья Геннадьевна Яковлева Resistance thin-film heater composition to use electromagnetic radiation for activating metabolism and stimulating human immune system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ali Farid M.Ali et al. Bee propolis as a new modality for treatment of H1N1 Influenza. // Journal of American Science.- 2013; 9(12). *
Ali Farid M.Ali et al. Bee propolis as a new modality for treatment of H1N1 Influenza. // Journal of American Science.- 2013; 9(12). Tomomi Shimizu et al. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice // Antiviral Chemistry & Chemotherapy.-2008.- 19:7-13. Лекарственные растения: фундаментальные и прикладные проблемы: материалы I Международной научной конференции (21-22 мая 2013 г., г. Новосибирск) / Новосиб. гос. аграр. ун-т. -Новосибирск: Изд-во НГАУ, 2013.- 537 с. Используем лечебные свойства травы аконит для своего здоровья. 17.10.2018. - [дата обращения: 02.07.2019], [интернет ресурс] https://glav-dacha.ru/lechebnye-svoystva-travy-akonit/. Штаммы и эпидемии гриппа. 23.01.2014. [дата обращения: 02.07.2019], [интернет ресурс] https://visual-science.com/ru/projects/influenza/illustration/. *
Tomomi Shimizu et al. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice // Antiviral Chemistry & Chemotherapy.-2008.- 19:7-13. *
Используем лечебные свойства травы аконит для своего здоровья. 17.10.2018. - [дата обращения: 02.07.2019], [интернет ресурс] https://glav-dacha.ru/lechebnye-svoystva-travy-akonit/. Штаммы и эпидемии гриппа. 23.01.2014. [дата обращения: 02.07.2019], [интернет ресурс] https://visual-science.com/ru/projects/influenza/illustration/. *
Лекарственные растения: фундаментальные и прикладные проблемы: материалы I Международной научной конференции (21-22 мая 2013 г., г. Новосибирск) / Новосиб. гос. аграр. ун-т. -Новосибирск: Изд-во НГАУ, 2013.- 537 с *

Similar Documents

Publication Publication Date Title
RU2434640C2 (en) Treatment of metastatic breast cancer
RU2356547C2 (en) Cancer therapy with using hdac inhibitors
EA201650134A1 (en) SPECIFIC COMBINED THERAPY OF MALIGNANT TUMORS BY CYTOSTATIC AND ITS MODIFIER
MX2022007371A (en) Hypoparathyroidism treatment.
RU2568582C1 (en) Method for non-specific immunoprophylaxis of bovine respiratory diseases
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
RU2711629C1 (en) Method for treating influenza and quinsy strains and composition for its implementation
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
Aminin et al. Radioprotective properties of cumaside, a complex of triterpene glycosides from the sea cucumber Cucumaria japonica and cholesterol
MX2021012543A (en) Chiral indole compounds and their use.
RU2711630C1 (en) Method of treating tuberculosis and composition for its implementation
CN105147770A (en) Composition having body odor removal function and preparation method and application thereof
RU2702124C2 (en) Method for prevention and therapy of otoacariasis of carnivores and rabbit psoroptic mange
RU2346696C2 (en) Method of human immune system stimulation using activated platinoids-containing mineral, method of mineral activation and composition with immune system stimulation properties
CN102731630A (en) Antioxidant oligopeptide with skin penetration capability
RU2713167C1 (en) Method of treating hepatitis and composition for implementation thereof
RU2702123C2 (en) Method for prevention and therapy of otoacariasis of carnivores and rabbit psoroptic mange
RU2589694C1 (en) Method for preventing and treating chronic fatigue syndrome
MX2021008658A (en) Solid forms of ttk inhibitor.
RU2423990C1 (en) Method of treating mastitis in cows
RU2612011C1 (en) Enterosorbent
RU2418581C1 (en) Application of musk deer musk tincture and ultraviolet irradiation of blood for treatment of spermatogenic failure in men of reproductive age
RU2161486C2 (en) Method of treatment of patients with radiation-thermal damage and agent for its realization
EA004603B1 (en) Method for preventing and treating diseases of an immune system and a remedy for carrying out said method
RU2339386C1 (en) Agent possessing selective radio- and chemoprotective action

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201107